Table 4.
Diagnostic parameters and concordance of malignant diagnostic groups.
| PD/AD | No. of Diagnoses during TDC | TP | FN | Cohen’s Kappa (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) |
NPV (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Malignant melanoma | ||||||||
| PD | 32 | 10 | 5 | 0.410 (0.231–0.589) |
66.7% (41.7–84.8%) |
97.1% (95.7–98.1%) |
31.3% (18.0–48.6%) |
99.3% (98.44–99.7%) |
| AD | 42 | 14 | 1 | 0.476 (0.317–0.636) |
93.3% (70.2–99.7%) |
96.3% (94.8–97.5%) |
33.3% (21.0–48.5%) |
99.9% (99.2–100.0%) |
| Squamous cell carcinoma | ||||||||
| PD | 36 | 13 | 8 | 0.437 (0.273–0.600) |
61.9% (40.9–79.3%) |
97.0% (95.5–98.0%) |
36.1% (22.5–52.4%) |
98.9% (97.9–99.5%) |
| AD | 45 | 19 | 2 | 0.560 (0.415–0.704) |
90.5% (71.1–98.3%) |
96.6% (95.0–97.7%) |
42.2% (29.0–56.7%) |
99.7% (99.0–100.0%) |
| Basal cell carcinoma | ||||||||
| PD | 98 | 70 | 8 | 0.770 (0.698–0.842) |
89.7% (81.1–94.7%) |
96.0% (94.3–97.2%) |
71.4% (61.8–79.4%) |
98.8% (97.7–99.4%) |
| AD | 112 | 71 | 7 | 0.714 (0.638–0.789) |
91.00% (82.6–95.6%) |
94.2% (92.2–95.7%) |
63.4% (54.2–71.7%) |
99.00% (97.9–99.5%) |
| Other malignancies | ||||||||
| PD | 8 | 5 | 2 | 0.663 (0.386–0.941) |
71.4% (35.9–94.9%) |
99.6% (98.9–99.9%) |
62.5% (30.6–86.3%) |
99.7% (99.1–99.9%) |
| AD | 8 | 5 | 2 | 0.663 (0.386–0.941) |
71.4% (35.9–94.9%) |
99.6% (98.9–99.9%) |
62.5% (30.6–86.3%) |
99.7% (99.1–100.0%) |
| Actinic keratosis | ||||||||
| PD | 25 | 20 | 11 | 0.704 (0.566–0.842) |
64.5% (47.0–78.9%) |
99.3% (98.4–99.7%) |
80.0% (60.9–91.1%) |
98.5% (97.4–99.2%) |
| AD | 33 | 24 | 7 | 0.739 (0.617–0.862) |
77.4% (60.2–88.6%) |
98.8% (97.7–99.4%) |
72.7% (55.8–84.9%) |
99.1% (98.1–99.5%) |
Abbreviations: PD: primary diagnostic, AD: aggregated diagnostic, No.: number, TDC: teledermatology consultations, TP: true positive, FN: false negative, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value.